<DOC>
	<DOCNO>NCT02096952</DOCNO>
	<brief_summary>The purpose study determine whether methylphenidate hydrochloride extend release liquid formulation safe effective treatment attention-deficit/hyperactivity disorder ( ADHD ) high-functioning adult autism spectrum disorder ( ASD ) .</brief_summary>
	<brief_title>Methylphenidate ER Liquid Formulation Adults With ASD ADHD</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Inclusion Criteria Male female participant 18 40 year age ( inclusive ) Fulfills DSM5 diagnostic criterion autism spectrum disorder establish clinical diagnostic interview ADOS Fulfills DSM5 diagnostic criterion ADHD establish clinical diagnostic interview confirm KSADSE ADHD module Participants least moderately severe symptom ASD demonstrate SRS raw score ≥ 85 CGIASD severity score ≥ 4 Participants least moderately severe symptom ADHD assess AISRS score ≥ 24 CGIADHD severity score ≥ 4 Participants and/or legal representative must understand nature study . Participants and/or legal representative must sign IRBapproved informed consent form initiation study procedure . Participants and/or legal representative must level understanding sufficient communicate investigator study coordinator , cooperate test examination require protocol . Participant must able participate mandatory blood draw . Participant major mood and/or anxiety disorder allow participate study provide meet exclusionary criterion . Exclusion Criteria Impaired intellectual capacity ( IQ &lt; 85 ) Participant unable communicate due delay , total lack , spoken language development ( grossly impair language skill ) Clinically unstable psychiatric condition judge serious safety risk self ( suicidal risk ) others ( within past 30 day ) . Subjects currently ( within past 30 day ) experience significant feature anxiety , mood , psychotic disorder indicate &gt; 3 score disorderspecific Clinical Global ImpressionSeverity ( CGIS ) clinicianrated scale . History substance use ( except nicotine caffeine ) within past 3 month ( inclusive ) urine drug screen positive substance abuse Subjects medical condition treatment either jeopardize subject safety affect scientific merit study , include : Pregnant nursing female female positive betaHCG pregnancy test . Uncorrected hypothyroidism hyperthyroidism . History nonfebrile seizure within last 1 month without clear resolve etiology . History renal hepatic impairment . Glaucoma Tourette 's syndrome and/or motor tic Serious , unstable systemic illness Personal history cardiac disease family history nongeriatric cardiac disease death Clinically significant abnormal baseline laboratory value include follow : Values 20 % upper range laboratory standard basic metabolic screen . Systolic diastolic blood pressure parameters 140 90 , respectively . Resting heart rate outside 60100 bpm . Abnormal ECG parameter define QTC &gt; 460msec , QRS &gt; 120 msec , and/or PR &gt; 200 msec . ECG evidence ischemia arrhythmia review independent cardiologist . Participant history nonresponse adequate trial methylphenidate ( therapeutic dose adequate duration ) determine clinician . History intolerance allergic reaction methylphenidate . Current recent treatment ( within past 30 day ) current stimulant class antiADHD medication . Current treatment monoamine oxidase inhibitor ( MAOIs ) Current treatment first secondgeneration antipsychotic medication dose stable least 4 week prior baseline visit . Current treatment psychotropic medication dose stable least 4 week prior baseline visit . Investigator his/her immediate family , define investigator 's spouse , parent , child , grandparent , grandchild . While stably treat remitted hypertension exclusionary , subject history high blood pressure ask obtain approval primary care physician certify hypertension stable may safely begin stimulant therapy . Subjects inform cardiovascular risk MPH , subject history hypertension unwilling consult current treater—or grant study staff permission consult subject 's current treater—will exclude potential risk subject safety . Per FDA approve MPHERLF package insert , high blood pressure contraindication MPH therapy ; however , due cardiovascular side effect , recommend subject history high blood pressure monitor carefully . Cardiovascular risk factor carefully monitor throughout study subject way screen electrocardiogram pulse/blood pressure reading every office visit . Patients current untreated hypertension eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Attention-deficit/hyperactivity disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Autism spectrum disorder</keyword>
	<keyword>ASD</keyword>
	<keyword>High-functioning ASD</keyword>
	<keyword>Asperger 's disorder</keyword>
	<keyword>Asperger 's</keyword>
</DOC>